title: Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases.
abstract: BACKGROUND
  Fluorine 18-fluoro-2-deoxyglucose (FDG) positron emission tomography ((18)F-FDG PET) can be used to visualize metastases in patients with differentiated thyroid carcinoma that does not take up radioiodine ((131)I). This study was aimed at evaluating the feasibility of (18)F-FDG radio-guided surgery in patients with radioiodine-negative differentiated thyroid cancer.
  
  
  METHODS
  Ten patients received a mean activity of 265 MBq of (18)F-FDG 30 minutes before operation. Radioactivity uptake (counts per second [cps], with a pretime of 10 seconds) in tumor and normal tissues was measured before and after resection.
  
  
  RESULTS
  Patients with 1 to 5 foci detected by FDG-PET were included in the study. Six of these patients were injected with recombinant human thyroid-stimulating hormone (TSH) preoperatively. Abnormal findings detected by preoperative (18)F-FDG PET were also detected with the gamma probe in all patients. The mean tumor activity in vivo was 3,272 cps, and tumor-to-neck and tumor-to-shoulder ratios were, respectively, 1.40 and 1.73. Tumor resection was incomplete in 3 patients. When resection was complete, mean radioactivity at the tumor site was decreased by 22%. The ex vivo mean tumor-to-normal tissue ratio was 2.4. All positive tissues detected with the probe were confirmed histologically to be differentiated thyroid cancer. The surgeon's hands were exposed to 90 to 270 microSv.
  
  
  CONCLUSIONS
  These results show the feasibility and benefit of (18)F-FDG radio-guided surgery with a gamma probe in the management of differentiated thyroid cancer patients with radioiodine-negative recurrence.
authors.affiliation: Department of Nuclear Medicine, Hôtel Dieu Hospital, Nantes, France.
authors.forename: Françoise
authors.initials: F
authors.lastname: Kraeber-Bodéré
authors.forename: Bertrand
authors.initials: B
authors.lastname: Cariou
authors.forename: Chantal
authors.initials: C
authors.lastname: Curtet
authors.forename: Boumediene
authors.initials: B
authors.lastname: Bridji
authors.forename: Caroline
authors.initials: C
authors.lastname: Rousseau
authors.forename: François
authors.initials: F
authors.lastname: Dravet
authors.forename: Bernard
authors.initials: B
authors.lastname: Charbonnel
authors.forename: Bruno
authors.initials: B
authors.lastname: Carnaille
authors.forename: Jean Claude
authors.initials: JC
authors.lastname: Le Néel
authors.forename: Eric
authors.initials: E
authors.lastname: Mirallié
mesh_terms: D018249:Adenoma, Oxyphilic / Q000000981:diagnostic imaging* / Q000556:secondary / Q000601:surgery*; D000328:Adult; D000368:Aged; D002291:Carcinoma, Papillary / Q000000981:diagnostic imaging* / Q000556:secondary / Q000601:surgery*; D005240:Feasibility Studies; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D007455:Iodine; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D025321:Surgery, Computer-Assisted; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D007455:Iodine